TOR2A: A Potential Drug Target for Cellular Processes (G27433)

Target Name: TOR2A

NCBI ID: G27433

TOR2A

TOR2A: A Potential Drug Target for Cellular Processes

TOR2A (Torsin family 2 member A) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of TOR2A is its potential as a drug target. The Torsin family is a well-established gene family that has been implicated in a number of cellular processes, including cell signaling, DNA replication, and stress response. The Torsin proteins are known for their ability to regulate the activity of key signaling pathways, including the PI3K/Akt pathway.

TOR2A is a member of the Torsin family and is expressed in a variety of tissues, including the brain, heart, and kidneys. It is involved in the regulation of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most promising aspects of TOR2A is its potential as a drug target. The Torsin family is a well-established gene family that has been implicated in a number of cellular processes, including cell signaling, DNA replication, and stress response. The Torsin proteins are known for their ability to regulate the activity of key signaling pathways, including the PI3K/Akt pathway.

The PI3K/Akt pathway is a key signaling pathway that is involved in a wide range of cellular processes, including cell proliferation, differentiation, and survival. The Torsin protein plays a key role in regulating the activity of this pathway by interacting with the protein Pyh1 (also known as PIK3CA), which is a negative regulator of the PI3K/Akt pathway.

TOR2A has been shown to play a role in the regulation of cell proliferation and has been implicated in the development of a number of diseases. For example, TOR2A has been shown to be highly expressed in cancer tissues and has been associated with the development of a variety of cancers, including breast, ovarian, and prostate cancers.

In addition to its role in cancer, TOR2A has also been implicated in the development of neurodegenerative diseases. For example, TOR2A has been shown to be highly expressed in the brains of individuals with Alzheimer's disease and has been associated with the development of this disease.

TOR2A has also been implicated in the development of autoimmune disorders. For example, TOR2A has been shown to be highly expressed in the tissues of individuals with rheumatoid arthritis and has been associated with the development of this disease.

In addition to its role in disease, TOR2A has also been shown to have potential as a drug target. The Torsin family is known for its ability to regulate the activity of key signaling pathways, including the PI3K/Akt pathway. As such, TOR2A has been shown to be a potential drug target by the pharmaceutical company Merck & Co.

The PI3K/Akt pathway is a key signaling pathway that is involved in a wide range of cellular processes, including cell proliferation, differentiation, and survival. The Torsin protein plays a key role in regulating the activity of this pathway by interacting with the protein Pyh1 (also known as PIK3CA), which is a negative regulator of the PI3K/Akt pathway.

TOR2A has been shown to play a role in the regulation of cell proliferation and has been implicated in the development of a number of diseases. For example, TOR2A has been shown to be highly expressed in cancer tissues and has been associated with the development of a variety of cancers, including breast, ovarian, and prostate

Protein Name: Torsin Family 2 Member A

The "TOR2A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TOR2A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets